** Shares of California-based diagnostic firm Bio-Rad BIO.N down 8.25% at $281.10
** Co reports Q4 sales of $667.5 million, missing analysts' estimate of $679.3 million, according to data compiled by LSEG
** Expects 2025 revenue growth of about 1.5% to 3.5% and operating margin of ~13% to 13.5%
** The forecast is mixed, as core growth bracketed expectations, but margins disappointed - Jefferies
** Co says will lay off about 5% of its workforce as a part of its restructuring plan - filing
** Adds will incur between about $45 million and $50 million in costs
** It reported Q4. adj profit of $2.9 vs est. $2.87
** In the last 12 months, the stock has fallen ~15%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。